SOPs for Drug Discovery

The purpose of this Standard Operating Procedure (SOP) is to outline the process of purifying proteins for structural studies in drug discovery. Protein purification is a critical step in the study of biomolecular structures and interactions, enabling the analysis of protein-ligand binding, enzymatic activity, and other molecular properties. This SOP ensures that protein purification is performed systematically and consistently to obtain high-quality protein samples suitable for downstream structural studies, such as X-ray crystallography, NMR spectroscopy, or cryo-EM.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of using X-ray crystallography for determining the three-dimensional structure of biomolecules, such as proteins, nucleic acids, and their complexes with drug candidates. X-ray crystallography is a powerful technique for resolving atomic-level structures, providing detailed information about ligand binding sites and molecular interactions. This SOP ensures that X-ray crystallography experiments are conducted systematically, with high-quality data that supports drug discovery and lead optimization.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of using Nuclear Magnetic Resonance (NMR) spectroscopy to determine the three-dimensional structure of biomolecules and drug candidates in solution. NMR spectroscopy is a powerful tool for obtaining detailed information about the molecular structure, dynamics, and interactions of proteins, nucleic acids, and small molecules. This SOP ensures that NMR experiments are performed consistently, with high-quality data generated to support drug discovery and lead optimization.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of using Cryo-Electron Microscopy (Cryo-EM) for studying biomolecular structures in drug development. Cryo-EM is a powerful technique for determining the three-dimensional structures of large macromolecular complexes and drug candidates at near-atomic resolution. This SOP ensures that Cryo-EM studies are conducted systematically and produce high-quality data, contributing to the structural understanding of drug targets and facilitating the development of novel drug candidates.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for performing Molecular Dynamics (MD) simulations in drug discovery. MD simulations provide a detailed, time-resolved view of molecular motion, helping to understand protein-ligand interactions, stability, conformational changes, and binding affinities. This SOP ensures that MD simulations are conducted systematically and efficiently to generate accurate data that supports the design and optimization of drug candidates.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the process of preparing binding affinity reports for drug discovery studies. Binding affinity reports provide critical information on the strength and specificity of interactions between a drug candidate (ligand) and its target protein. This SOP ensures that binding affinity reports are generated consistently, accurately, and in a format that supports drug optimization and decision-making during the drug discovery process.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting preclinical efficacy studies using cell lines in drug development. Preclinical efficacy studies assess the biological activity and potential therapeutic effects of drug candidates in vitro, providing important insights into their mechanism of action and therapeutic potential. This SOP ensures that these studies are conducted systematically, with accurate and reproducible results to support further drug development and clinical trials.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to describe the process of identifying early-stage biomarkers in drug discovery. Biomarkers are biological molecules or indicators that provide insight into disease progression, drug efficacy, and safety. Early-stage biomarker identification plays a critical role in the development of novel therapeutic candidates, guiding both preclinical and clinical development stages. This SOP ensures that biomarkers are identified systematically, reliably, and reproducibly, supporting the discovery of promising drug candidates.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for screening enzyme inhibitors in drug discovery. Enzyme inhibitors are crucial tools in developing therapeutic agents for diseases where enzymes play a key role in disease progression. This SOP ensures that enzyme inhibitor screening is conducted systematically and that the results are reliable, reproducible, and interpretable to identify promising drug candidates for further development.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the process for conducting high-content screening (HCS) methods in drug discovery. HCS is a powerful technique that allows for the simultaneous measurement of multiple cellular events, providing comprehensive insights into drug effects on cellular morphology, viability, and other cellular parameters. This SOP ensures that HCS experiments are performed systematically, yielding reproducible and high-quality data for the identification of novel drug candidates.
Click to read the full article.